Alexion Receives FDA Approval of Soliris (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder

FDA News, New FDA Approvals
June 27, 2019
A+ A-
Email Print

Article Link: Alexion Receives FDA Approval of Soliris (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder

BOSTON–(BUSINESS WIRE)–June 27, 2019 — Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Soliris (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult…

Source: FDA New Drug Approvals

Posted by

Newer Post
Older Post